

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/26070>

Please be advised that this information was generated on 2019-11-12 and may be subject to change.

LETTERS

Increased Soluble Interleukin-2 Receptor Concentrations in Patients with Insulin-dependent Diabetes Mellitus

The central pathogenetic event in insulin-dependent (Type 1) diabetes mellitus (IDDM) is the T-lymphocyte-mediated destruction of insulin-producing β -cells. Antigenic stimulation of T-lymphocytes results in both production of interleukin-2 (IL-2) and expression of IL-2 receptors (IL-2R). During the activation of T-lymphocytes, a 42-kD fragment of IL-2R is cleaved off and circulates as a soluble marker of lymphocyte activation (sIL-2R). Several studies have investigated the presence of sIL-2R in IDDM patients, with conflicting results. While some studies reported increased concentrations,^{1,2} other investigators have found lower levels of circulating sIL-2R in IDDM patients when compared with normal volunteers.³ The aim of our study was to assess the sIL-2R concentrations in newly diagnosed IDDM (ND-IDDM) and long-standing IDDM (LS-IDDM) patients, and compare them with sIL-2R levels in healthy controls.

Thirteen ND-IDDM patients (7 men and 6 women; mean age 22 (13–23) years), and 14 LS-IDDM patients (8 men and 7 women; mean age 28 (12–37) years) were investigated. The ND-IDDM patients were investigated within 10 days of diagnosis, after the metabolic state was stabilized. The duration of diabetes in the LS-IDDM group was longer than 1 year. Serum fasting C-peptide levels were below 0.1 nmol l⁻¹ in all patients. Sixteen healthy volunteers (9 men, 7 women, mean age 23 (19–28) years) represented the control group. Serum sIL-2R concentrations were determined using a two-site enzyme immunoassay (Boehringer-Mannheim, Germany); detection limit was 20 pmol l⁻¹. Values are given as mean \pm standard deviation. Differences were compared using Kruskal-Wallis test and considered significant at $p < 0.05$.

The sIL-2R concentrations were significantly higher in IDDM patients when compared with healthy controls (120.4 ± 61.4 vs 81.9 ± 26.2 pmol l⁻¹, $p = 0.0188$). The sIL-2R concentrations were increased in both ND-IDDM and LS-IDDM patients when compared with controls, but no significant difference could be found between the two groups of patients (112.6 ± 56.5 vs 127.7 ± 66.9 pmol l⁻¹, $p = 0.5121$). No correlation between sIL-2R and the metabolic status (glycemia and glycated haemoglobin) could be found.

In conclusion, sIL-2R concentrations are increased in patients with IDDM, and this is not correlated with the metabolic status. This is in accordance with some earlier studies,^{1,2} while being contradictory with the report of Wagner *et al.* which has shown the opposite.³ The difference with this last study is difficult to explain, but differences in genetic background of the patients or the method of sIL-2R assay may be the cause. sIL-2R concentrations were higher in both ND- and LS-IDDM patients when compared with controls, arguing for a continuous activation of the T-cells in Type 1 diabetes. The increased *in vivo* cleavage of sIL-2R from activated lymphocytes is very probably the cause for the reported defective *in vitro* production of sIL-2R by cells of IDDM patients.⁴ The higher concentrations of sIL-2R (by shedding from IL-2-responsive T lymphocytes) in IDDM patients may represent an argument for the importance of IL-2 in the pathogenesis of Type 1 diabetes. Although several studies have shown that IL-2 production is impaired in IDDM patients,^{5,6} this might not represent the real situation at the tissue level. Thus, it has been recently shown that the Th1 lymphocyte subset (producing high levels of IL-2 and IFN- γ) actively promote diabetes in neonatal NOD mice,⁷ while autoimmune diabetes develops in transgenic mice expressing IL-2 and class I molecule H-2K^b in their β -cells.⁸

Mihai G. Netea^a, Nicolae Hancu
Diabetes Center and Clinic
Str. Clinicilor nr. 2,
3400 Cluj-Napoca, Romania

References

- Giordano C, Galuzzo A, Marco A, Panto F, Amato MP, Caruso C, Bompiani GD. Increased soluble interleukin-2 receptor levels in the sera of type 1 diabetic patients. *Diabetes Res* 1988; **8**: 135–138.
- Burke GW, Cirocco R, Markou M, Agramonte RF, Rabinovitch A, Miller J, Skyler JS. Effect of cyclosporin A on serum tumor necrosis alpha in new-onset type 1 (insulin-dependent) diabetes mellitus. *J Diabetes Complications* 1994; **8**: 40–44.
- Wagner R, Bonifacio E, Bingley PJ, Genovese S, Reinwein D, Botazzo GF. Low interleukin-2 receptor levels in serum of patients with insulin-dependent diabetes. *Clin Invest* 1994; **72**: 494–498.
- Giordano C, Panto F, Caruso C, Modica MA, Zambito AM, Sapienza M, *et al.* Interleukin 2 and soluble interleukin 2-receptor secretion defect *in vitro* in newly diagnosed type 1 diabetic patients. *Diabetes* 1989; **38**: 310–315.
- Zier KS, Leo MM, Spielman RS, Baker L. Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. *Diabetes* 1984; **33**: 552–555.
- Kaye WA, Adri MNS, Soeldner JS, Rabinowe SL, Kaldany A, Kahn R, *et al.* Acquired defect in interleukin-2 production in patients with type 1 diabetes mellitus. *N Engl J Med* 1986; **315**: 920–924.
- Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. *Science* 1995; **268**: 1185–1188.
- Heath HR, Allison J, Hoffmann MW, Schonrich G, Hammerling G, Arnold B, Miller JFAP. Autoimmune diabetes as a consequence of locally produced interleukin-2. *Nature* 1992; **359**: 547–549.

We Require a British Prevention of Diabetes Complications Trial

Diabetes results in increased risk of heart, renal, ophthalmic, cerebrovascular disease and neuropathy with peripheral vascular disease. It is conceivable that a large proportion—perhaps some 80%—of the associated morbidity and financial cost is avoidable by decreasing the rate of complications seen in people with diabetes to that of the non-diabetic population. This is possible because people with diabetes are more than four times as likely to be admitted to hospital, and they stay on average almost twice as long as people who do not have diabetes.¹ There is evidence from the Diabetes Control and Complications Trial that microvascular disease complication-rates can be reduced in Type 1 diabetes.² However, strictly speaking, the financial cost of Type 1 diabetes is less important than Type 2 diabetes which strikes at a ratio of some 3 : 1 people, and in older age groups.

A forthcoming Kings Fund report will publish an estimate of the annual hospital expenditure for diabetes at some 8% of NHS expenditure, or roughly £2 billion.³ This disguises the less tangible costs of disease morbidity in terms of reduced quality of life, psychological ill-health, and decreased working productivity.

Studying a disease with the complexity of diabetes involves many unusual problems. For example, onset is usually insidious, the wide variety of vascular complications may only manifest themselves after a number of years in a state of